Trial Profile
Basophil Cd203c Expression as an Immunological Marker to Predict Response to Treatment with Omalizumab in Patients with Symptomatic Chronic Urticaria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2016
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Biomarker; Therapeutic Use
- 15 Mar 2016 New trial record